Trinity Biotech (TRIB) Total Current Liabilities (2009 - 2025)

Trinity Biotech (TRIB) has reported Total Current Liabilities for 17 consecutive years, with $141.2 million the latest figure, recorded in Q4 2025.

• Quarterly Total Current Liabilities rose 339.97% year-over-year to $141.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $141.2 million (up 339.97% YoY) and the FY2025 annual result came in at $141.2 million, up 339.97% from the prior year.
• Total Current Liabilities climbed to $141.2 million in Q4 2025 per TRIB's latest filing, from $31.5 million in the prior quarter.
• Over the last five years, Total Current Liabilities for TRIB reached as high as $141.2 million in Q4 2025 and fell as low as $12.7 million in Q3 2023.
• A 5-year average of $41.3 million and a median of $24.3 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Current Liabilities soared 364.27% — and 2022, when it plunged 86.86%.
• Year by year, Total Current Liabilities stood at $100.5 million in 2021, then plunged by 82.75% to $17.3 million in 2022, then fell by 13.29% to $15.0 million in 2023, then surged by 113.47% to $32.1 million in 2024, then soared by 339.97% to $141.2 million in 2025.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $141.2 million, $31.5 million, and $32.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.